Evidence map›Paper›PMID 22025149›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.

Alberto S Pappo, Shreyaskumar R Patel, John Crowley, Denise K Reinke, Klaus-Peter Kuenkele, Sant P Chawla, Guy C Toner, Robert G Maki, Paul A Meyers, Rashmi Chugh and 8 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
196citing papers in PubMed, 4 pooled it
29.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

196 citing papers in PubMed, 4 syntheses or guidelines pooled it, 318 citations in OpenAlex.

  1. Pooled it
  2. Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Teprotumumab for Thyroid-Associated Ophthalmopathy.The New England journal of medicine · 2017
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

136 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 3 countries.

Alberto S PappoSt Jude Children’s Research Hospital, Memphis, TN, USA. bakerl@umich.edu
Shreyaskumar R Patel
John Crowley
Denise K Reinke
Klaus-Peter Kuenkele
Sant P Chawla
Guy C Toner
Robert G Maki
Paul A Meyers
Rashmi Chugh
Kristen N Ganjoo
Scott M Schuetze
Heribert Juergens
Michael G Leahy
Birgit Geoerger
Robert S Benjamin
Lee J Helman
Laurence H Baker
Institut Gustave Roussy · FRNational Health Service · GBNational Institutes of Health · US

Funding

Molecular Biology of Pediatric TumorsZIASC006892 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI HELMAN, LEE J. · 2009 to 2017
$6.3M
Solid TumorsZIASC006891 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI HELMAN, LEE J. · 2009 to 2017
$5.0M
6 · The paper itself

Abstract

purposeThe type 1 insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the pathogenesis of the Ewing sarcoma family of tumors (ESFT). We conducted a multicenter phase II study of the fully human IGF-1R monoclonal antibody R1507 in patients with recurrent or refractory ESFT. PATIENTS AND

methodsPatients ≥ 2 years of age with refractory or recurrent ESFT received R1507 at doses of 9 mg/kg intravenously one a week or 27 mg/kg intravenously every three weeks. Response was measured by using WHO criteria. Tumor imaging was performed every 6 weeks for 24 weeks and then every 12 weeks.

resultsFrom December 2007 through April 2010, 115 eligible patients from 31 different institutions were enrolled. The median age was 25 years (range, 8 to 78 years). The location of the primary tumor was bone in 57% of patients and extraskeletal in 43% of patients. A total of 109 patients were treated with R1507 9 mg/kg/wk, and six patients were treated with 27 mg/kg/3 wk. The overall complete response/partial response rate was 10% (95% CI, 4.9% to 16.5%). The median duration of response was 29 weeks (range, 12 to 94 weeks), and the median overall survival was 7.6 months (95% CI, 6 to 9.7 months). Ten of 11 responses were observed in patients who presented with primary bone tumors (P = .016). The most common adverse events of grades 3 to 4 were pain (15%), anemia (8%), thrombocytopenia (7%), and asthenia (5%).

conclusionR1507 was a well-tolerated agent that had meaningful and durable benefit in a subgroup of patients with ESFT. The identification of markers that are predictive of a benefit is necessary to fully capitalize on this approach.

Indexed as

AdolescentAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBone NeoplasmsChildDrug Administration ScheduleHumansMiddle AgedReceptor, IGF Type 1RecurrenceSarcoma, EwingTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsReceptor, IGF Type 1teprotumumab

Identifiers

PMID22025149
PMCPMC3236654
OpenAlexW2044313879

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.